Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company,基蛋生物, within the medical device industry [1][2] - As of August 22, the company's stock closed at 8.83 yuan, down 2.11%, with a rolling PE ratio of 22.18 times and a total market capitalization of 4.478 billion yuan [1] - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing the company at the 47th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, the number of shareholders for the company is 26,747, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field [1] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1]

Group 1 - The core viewpoint of the articles highlights the current financial performance and market position of 基蛋生物, indicating a significant decline in revenue and profit compared to the previous year [1][2] - As of August 19, 基蛋生物's closing stock price was 8.9 yuan, with a PE ratio of 22.35, marking a new low in 165 days, and a total market capitalization of 4.514 billion yuan [1] - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, positioning 基蛋生物 at 46th place within the industry [1][2] Group 2 - For the first quarter of 2025, 基蛋生物 reported revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24% year-on-year, with a gross margin of 77.15% [1] - The company is primarily engaged in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field in China [1] - As of March 31, 2025, 基蛋生物 had 26,747 shareholders, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

基蛋生物科技股份有限公司主要从事体外诊断试剂与仪器的研发、生产、销售及服务，是国家火炬计划 重点高新技术企业，是国内体外诊断领域（尤其是POCT领域）主要的供应商之一。公司目前主要产品 为自主研发的POCT体外诊断试剂及配套仪器。此外，发行人实现了部分生化乳胶体外诊断试剂产品试 产并开始销售。 最新一期业绩显示，2025年一季报，公司实现营业收入2.44亿元，同比-24.08%；净利润6430.74万元， 同比-25.24%，销售毛利率77.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13基蛋生物21.7719.661.6443.97亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿 ...

最新一期业绩显示，2025年一季报，公司实现营业收入2.44亿元，同比-24.08%；净利润6430.74万元， 同比-25.24%，销售毛利率77.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13基蛋生物22.2520.091.6744.93亿行业平均 54.3250.504.72116.17亿行业中值38.1137.682.7056.52亿1九安医疗10.9911.120.87185.49亿2新华医疗 15.9814.821.30102.47亿3英科医疗16.0817.331.43254.01亿4山东药玻16.1016.151.85152.30亿5振德医疗 16.4615.511.0559.74亿6奥美医疗16.5616.231.7059.84亿7康德莱17.8617.871.4838.48亿8九强生物 17.9416.682.2088.83亿9维力医疗18.0819.322.2742.38亿10奥泰生物18.1519.131.4757.88亿11鱼跃医疗 19.9219.542.69352.87亿12安图生物20.2719.352.60231.08亿 股东方面，截至2025年3月31 ...

Core Viewpoint - The stock of Jiedan Bio closed at 8.65 yuan, up 1.88%, with a rolling PE ratio of 21.72, marking a new low in 76 days, and a total market capitalization of 4.387 billion yuan [1] Company Summary - Jiedan Bio primarily engages in the research, production, sales, and service of in vitro diagnostic reagents and instruments, recognized as a key high-tech enterprise under the National Torch Program [1] - The company is a major supplier in the domestic in vitro diagnostic field, particularly in the POCT sector, with its main products being self-developed POCT in vitro diagnostic reagents and supporting instruments [1] - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross profit margin of 77.15% [1] Industry Summary - The average PE ratio for the medical device industry is 54.56, with a median of 37.54, placing Jiedan Bio at 47th in the industry ranking [2] - The static PE ratio for Jiedan Bio is 19.62, and the price-to-book ratio is 1.63 [2] - The average market capitalization for the industry is 11.396 billion yuan, with Jiedan Bio's market cap at 4.387 billion yuan [2]

Group 1 - The core viewpoint of the news highlights the current performance and market position of the company, Jidan Biotechnology, in the medical device industry, noting its low PE ratio compared to industry averages [1] - As of July 16, Jidan Biotechnology's closing price was 8.38 yuan, with a PE ratio of 21.05, marking a new low in 70 days, and a total market capitalization of 4.25 billion yuan [1] - The company ranks 48th in the medical device industry, which has an average PE ratio of 51.87 and a median of 37.48 [1] Group 2 - Jidan Biotechnology primarily engages in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field [1] - The latest quarterly report for Q1 2025 shows the company achieved revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1] - As of the Q1 2025 report, four institutions held shares in Jidan Biotechnology, totaling 28.14 million shares with a market value of 236 million yuan [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Jidan Biotechnology, which closed at 8.19 yuan with a rolling PE ratio of 20.57, marking a new low in 21 days, and a total market capitalization of 4.154 billion yuan [1] - The average PE ratio for the medical device industry is 51.40, with a median of 37.27, positioning Jidan Biotechnology at the 48th rank within the industry [1] - As of March 31, 2025, Jidan Biotechnology had 26,747 shareholders, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Jidan Biotechnology primarily engages in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the domestic in vitro diagnostic field, especially in the POCT sector [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1] - The PE ratios of other companies in the industry range from 10.28 to 20.57, with Jidan Biotechnology's PE ratio being lower than the industry average and median [2]

Company Overview - Company name is 基蛋生物科技股份有限公司, primarily engaged in the research, production, sales, and service of in vitro diagnostic reagents and instruments [1] - The company is recognized as a key high-tech enterprise under the National Torch Program and is a major supplier in the domestic in vitro diagnostic field, particularly in the POCT sector [1] Financial Performance - As of the latest quarterly report for Q1 2025, the company achieved revenue of 244 million yuan, representing a year-on-year decrease of 24.08% [1] - The net profit for the same period was 64.31 million yuan, down 25.24% year-on-year, with a sales gross margin of 77.15% [1] Market Position - The company's stock closed at 8.19 yuan, with a PE ratio of 20.57 times, while the average PE ratio for the medical device industry is 49.64 times [1][2] - The total market capitalization of the company is 4.154 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders is 26,747, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]

最新一期业绩显示，2025年一季报，公司实现营业收入2.44亿元，同比-24.08%；净利润6430.74万元， 同比-25.24%，销售毛利率77.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)48基蛋生物20.3718.391.5341.13亿行业平均 50.0645.924.67106.84亿行业中值36.8038.232.4947.95亿1天益医疗-1755.47-3006.931.8722.37亿2澳华内 镜-607.09304.494.8663.98亿3诺唯赞-411.11-486.242.2687.98亿4爱朋医疗-375.90285.574.5330.84亿5博晖 创新-326.83518.633.4947.95亿6硕世生物-135.76-1983.751.2239.71亿7奥精医疗-124.17-182.001.6423.04亿 8睿昂基因-99.13-81.391.4112.83亿9康泰医学-85.34-72.113.0556.17亿10中红医疗-70.04-55.860.8948.67亿 11华大智造-63.84-56.654.40340.38亿 来源：金融界 5月13 ...